Navigation Links
Inostics DNA Blood Test Provides a More Precise Picture of Resistance Mutations Than Traditional Biopsies
Date:4/9/2013

BALTIMORE and HAMBURG, Germany, April 9, 2013 /PRNewswire/ --

A study presented at the AACR Annual Meeting 2013 indicates that a DNA blood test using Inostics' BEAMing Digital PCR can detect more mutations associated with secondary drug resistance in GIST patients than testing conventional biopsies.

Therapies targeted to specific cancer-causing mutations may be the most promising strategy in cancer treatment. However, inter- and intra-tumor heterogeneity pose a significant challenge to maximizing therapeutic efficacy. Within a single patient, different cancer cells may have different sets of mutations making it very difficult to detect all of the relevant mutations in a single tissue biopsy.  

"To develop the right drug for the right patient, and to use those drugs most effectively, we need to understand the tumor burden in patients as fully as possible. Inostics' BEAMing technology may offer physicians a real-time composite picture of all the mutations across all tumors in any given patient using just a simple blood sample", George D. Demetri , M.D., Director of the Ludwig Center at Dana-Farber Cancer Institute and Harvard Medical School in Boston, Mass., said.

Demetri refers to data from a sub-analysis of the phase III GIST-Regorafenib in Progressive Desease (GRID) trial, designed to assess the efficacy of regorafenib in patients with GIST. Comparing conventional sequencing on tumor tissue with data generated using the BEAMing technology on blood samples they found resistance mutations 4 times more often in blood samples (48%) than in tumor tissue samples (12%). Furthermore, nearly half of the blood samples that had secondary KIT mutations harbored multiple secondary mutations.  "By using this technology we hope to develop the most rational drug combinations and better tests to match patients with the most effective therapies going forward", Demetri said.

BEAMing technology is a combination of digital PCR and flow cytometry originally developed by the group of Bert Vogelstein , M.D. at The Johns Hopkins University. Inostics licensed the technology and adopted it for routine use. Understanding the need of even more comprehensive coverage for the detection of de novo resistance mutations, Inostics is currently developing a sequencing based technology. "We are combining our expertise for highly sensitive mutation detection using BEAMing with the power of sequencing to hopefully detect all potential primary and secondary resistant mutations in the KIT gene in the near future" said Philipp Angenendt , Ph.D., Chief Technology Officer of Inostics.

BEAMing is the most sensitive and quantitative technology available today for the detection of tumor specific somatic mutations in blood samples. Inostics' BEAMing services are readily available to support clinical trials and research in oncology and have been successfully used on over 5000 samples in >34 clinical trials. Furthermore, Inostics offers BEAMing as a CLIA certified laboratory developed test for routine clinical analysis.

For more information on blood testing and the BEAMing Digital PCR technology refer to http://www.inostics.com or email us at info@inostics.com

Press contact:

Inostics
Friederike Lehmann , PhD
Marketing & Licensing
Phone +49-(0)40-413383-90
Fax +49-(0)40-413383-99
lehmann@inostics.com
http://www.inostics.com


'/>"/>
SOURCE Inostics GmbH
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Haemonetics Signs Definitive Agreement to Acquire Pall Corporations Blood Collection, Filtration and Processing Product Lines For $551 Million
2. National Jewish Health, the Nations Premier Respiratory Hospital, Announces Lung Cancer Screening Trial Using Blood Test and CT
3. Blood Disorders: European Hematologists Gather in Amsterdam, June 14-17, 2012
4. Failure to Take Medicine Linked to Unnecessary Hospital Visits, Especially for Medicare Patients Taking High Blood Pressure or High Cholesterol Medications
5. NuMe Health Completes $1.5 Million Series A Financing To Advance Its First Cobiotic™ Aimed At Helping Prediabetics Maintain Healthy Blood Glucose Levels
6. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
7. Glooko Launches the Glooko™ IR Adapter to Give ACCU-CHEK® Blood Glucose Meter Customers Access to the Glooko Logbook Solution
8. OICR funds Fluorinov Pharma Inc. to further develop its novel drug for the treatment of blood cancers
9. Spot On Sciences Awarded $1 Million DARPA Grant to Develop a Blood Sample Collection Device
10. Diabetes Care Devices in Emerging Countries (China, India, Brazil) to 2017 - Greater Awareness is Increasing Demand for Self-Monitoring of Blood Glucose (SMBG) in the Home Care Segment
11. Global Growth Factors (Blood And Tissue) Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)...   Hudes Laser Aesthetica announced their ... Astanza Trinity laser and Astanza Liberty IPL technologies. ... removal, IPL hair removal, pigmented and vascular lesion ... Aesthetica is setting high standards for aesthetic clinics ... to deliver effective, long-lasting results. "Hudes ...
(Date:12/9/2016)... Fla. , Dec. 9, 2016  Harmar Mobility, LLC announced ... and a member of the Board of Directors. Photo ... ... Mr. Dawson,s ... development of organizations across a variety of industries. He brings to ...
(Date:12/9/2016)... DUBLIN , Dec 9, 2016 Research ... Vaccines Market 2016-2020" report to their offering. ... The global travel vaccines market ... The report covers the present scenario and the growth ... the market size, the report considers the revenue generated from the ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... Premier Fitness Camp (PFC) ... , the ultimate weight loss and wellness program, at their world headquarters of Omni ... provide immediate and long-term results to anyone seeking weight loss, personal development, a healthy ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... development continuity to its innovative Unified Instance Manager architecture, meeting the needs ... this new version optimizes the unattended auto-dialing system without agents, Presence Robodialer, ...
(Date:12/8/2016)... ... December 08, 2016 , ... STATEN ISLAND, N.Y., Nov. ... adherence to the highest standards of trauma, maternity, cancer and chronic obstructive pulmonary ... and CEO, Dr. Daniel Messina. , Among the recognitions, the American College of ...
(Date:12/8/2016)... ... December 08, 2016 , ... California Senate Bill (SB) 863, ... workers’ compensation claim in 2013 and 2014, according to CompScope™ Medical Benchmarks for ... . , According to the study, medical payments per claim in California decreased 4 ...
(Date:12/8/2016)... ... December 08, 2016 , ... Healthcare is ... Dr. Botelho advocates for the mass media launching of story movements to highlight ... to share their unfortunate experiences; such a movement can generate the network power ...
Breaking Medicine News(10 mins):